Phase I Study of PEG-Paclitaxel In Patients With Advanced Solid Tumors & Lymphomas

Phase 1TerminatedNCT00023166

Enzon Pharmaceuticals, Inc.

Overview

Studies of PEG-paclitaxel have been terminated

Study Type

INTERVENTIONAL

Allocation

NON_RANDOMIZED

Purpose

TREATMENT

Masking

NONE

Sex: ALLMin age: 18 Years

Medical Language ↔ Plain English

None - Study has been terminated.

This platform is for informational purposes only and does not constitute medical advice. Always consult a qualified healthcare professional.